NKBR College of Pharmacy and Research Centre, Meerut, Uttar Pradesh, 45206, India.
ULTI Pharmaceuticals, Hamilton, 3204, New Zealand.
Drug Deliv Transl Res. 2018 Feb;8(1):97-110. doi: 10.1007/s13346-017-0440-1.
MicroRNAs (miRNAs) represent a new class of diagnostic and prognostic biomarker as well as new therapeutic targets in cancer therapy. miRNAs are gaining significant interest due to extensive advancements in knowledge since their discovery and, more recently, their translational application as therapeutic moieties and targets in the management of disease. miRNAs used in the treatment of cancer would position them as a new class of emerging therapeutic agents. Indeed, numerous candidate miRNAs have been identified as having therapeutic application in the treatment of cancer, but there is still much to learn about how to transform these into effective, patient-compliant, and targeted drug delivery systems. In this mini review, we discuss the utility and potential of nanotechnology in miRNA formulation and delivery with particular emphasis on cancer, including their role in conferring multidrug resistance and metastatic capacity. This review benefits both the formulation and biological scientists in understanding and exploring the new vistas of miRNA delivery using nanotechnology in the cancer clinically.
微小 RNA（miRNAs）作为癌症治疗中的诊断和预后生物标志物以及新的治疗靶点，代表了一类新的治疗药物。由于 miRNA 自发现以来的知识不断深入，以及最近作为治疗药物和疾病治疗靶点的转化应用，它们引起了广泛关注。用于癌症治疗的 miRNA 将使它们成为一类新的治疗药物。事实上，已经有许多候选 miRNA 被确定具有治疗癌症的应用，但对于如何将它们转化为有效的、患者依从性高的、靶向药物输送系统，还有很多需要了解。在这篇小型综述中，我们讨论了纳米技术在 miRNA 制剂和递送上的应用及其在癌症中的潜在应用，包括它们在赋予多药耐药性和转移能力方面的作用。这篇综述使制剂和生物学科学家都能理解和探索利用纳米技术在癌症临床中进行 miRNA 传递的新视野。
